 SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 GLOBE NEWSWIRE -- Calithera Biosciences, Inc. Nasdaq: CALA, a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from a trial evaluating the arginase inhibitor INCB001158, which is being developed by Incyte Pharmaceuticals, will be presented in a virtual poster session at the American Society of Clinical Oncology ASCO 2021 Gastrointestinal Cancers Virtual Symposium taking place January 15-17, 2021. 